US › Healthcare

ADC Therapeutics SA (ADCT)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$1.10+4.76%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$20.9M
Revenue YoY
-9.5%
Net profit
$-33.0M
Profit YoY
+14.6%
EPS
$-0.21
EPS estimate
$-0.20
Net margin
-158.1%

EPS came in at -0.21 against a street estimate of -0.20 — a miss of 5.0%.

Key statistics

Market cap
$133.6M
Forward P/E
0.0
P/B
3.42
Book value
$-1.70
EPS (TTM)
$-0.97
52-week high
$4.98
52-week low
$0.78
50-day MA
$1.59
200-day MA
$3.34
Beta
1.88

Analyst view

Analysts rate ADC Therapeutics SA a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $5.00.

Shareholding

Insiders
14.47%
Institutions
67.84%

Largest institutional holders

FundStake
Redmile Group, LLC12.16%
TCG Crossover Management, LLC8.96%
Prosight Management, LP6.53%
BlackRock Inc4.91%
Eventide Asset Management, LLC4.48%
Nantahala Capital Management, LLC4.40%
Morgan Stanley - Brokerage Accounts3.00%
Point72 Asset Management, L.P.2.66%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for ADC Therapeutics SA — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.